MCL Literature Feed

2 papers on mantle cell lymphoma from PubMed. Updated daily.

ADC BCL2i BTKi CAR-T CDK4/6i CNS MRD PI3Ki TP53-mutated biomarkers bispecific blastoid case report chemotherapy consolidation elderly epidemiology frontline genomics guidelines

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

Preclinical models show the PI3K inhibitor idelalisib synergizes with the CDK4/6 inhibitor palbociclib, providing a rationale for a novel combination therapy in relapsed/refractory MCL.

Dingyao Hu, Jiaowu Cao, Hui Yu et al.·Cancer letters·Aug 10, 2024

PI3Ki CDK4/6i relapsed/refractory preclinical biomarkers

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.

Palbociclib plus venetoclax shows preclinical synergy in ibrutinib-refractory MCL by downregulating MCL1, offering a chemo-free option for patients without RB1 deletion.

Diana Malarikova, Radek Jorda, Kristyna Kupcova et al.·Experimental hematology & oncology·Mar 25, 2024

CDK4/6i BCL2i relapsed/refractory preclinical biomarkers resistance